Alligator Bioscience AB Total Assets
Alligator Bioscience AB total assets. Based on the latest financial reports, Alligator Bioscience AB (ATORX) holds total assets worth Skr65.11 Million SEK (≈ $7.01 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Alligator Bioscience AB market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Alligator Bioscience AB (2005–2025)
Total assets of Alligator Bioscience AB from 2005 to 2025. This chart illustrates how Alligator Bioscience AB's total assets have evolved over time, based on quarterly financial data. See Alligator Bioscience AB stock quote for real-time trading data and today's change.
Alligator Bioscience AB - Asset Composition Analysis
Alligator Bioscience AB Total Assets Breakdown (December 2025)
Alligator Bioscience AB total assets breakdown as of December 2025. Alligator Bioscience AB's total assets of Skr65.11 Million consist of 62.1% current assets and 37.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr62.20 Million | 56.2% |
| Accounts Receivable | Skr6.46 Million | 5.8% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr1.87 Million | 1.7% |
| Intangible Assets | Skr40.07 Million | 36.2% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Alligator Bioscience AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ATORX working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alligator Bioscience AB's current assets represent 62.1% of total assets in 2025, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 56.2% of total assets in 2025, up from 41.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 36.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is cash and equivalents at 56.2% of total assets.
Alligator Bioscience AB Competitors by Total Assets
Key competitors of Alligator Bioscience AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Alligator Bioscience AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 0.46 | 2.22 |
| Quick Ratio | 0.58 | 0.46 | 2.07 |
| Cash Ratio | 0.00 | 0.37 | 1.86 |
| Working Capital | Skr-16.96 Million | Skr-49.30 Million | Skr51.81 Million |
Alligator Bioscience AB - Advanced Valuation Insights
This section examines the relationship between Alligator Bioscience AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.67 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 6.0% |
| Total Assets | Skr110.60 Million |
| Market Capitalization | $1.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Alligator Bioscience AB's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Alligator Bioscience AB's assets grew by 6.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Alligator Bioscience AB (2005–2025)
The table below shows the annual total assets of Alligator Bioscience AB from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr110.60 Million ≈ $11.90 Million |
+6.00% |
| 2024-12-31 | Skr104.34 Million ≈ $11.23 Million |
-11.91% |
| 2023-12-31 | Skr118.45 Million ≈ $12.75 Million |
-30.15% |
| 2022-12-31 | Skr169.58 Million ≈ $18.25 Million |
-49.10% |
| 2021-12-31 | Skr333.20 Million ≈ $35.86 Million |
+119.30% |
| 2020-12-31 | Skr151.94 Million ≈ $16.35 Million |
-51.17% |
| 2019-12-31 | Skr311.13 Million ≈ $33.48 Million |
-38.77% |
| 2018-12-31 | Skr508.16 Million ≈ $54.69 Million |
-20.98% |
| 2017-12-31 | Skr643.03 Million ≈ $69.20 Million |
-8.24% |
| 2016-12-31 | Skr700.78 Million ≈ $75.42 Million |
+68.35% |
| 2015-12-31 | Skr416.26 Million ≈ $44.80 Million |
+325.65% |
| 2014-12-31 | Skr97.79 Million ≈ $10.52 Million |
+219.39% |
| 2011-12-31 | Skr30.62 Million ≈ $3.30 Million |
+219.58% |
| 2010-12-31 | Skr9.58 Million ≈ $1.03 Million |
-50.96% |
| 2008-12-31 | Skr19.54 Million ≈ $2.10 Million |
-59.17% |
| 2007-12-31 | Skr47.85 Million ≈ $5.15 Million |
+176.74% |
| 2006-12-31 | Skr17.29 Million ≈ $1.86 Million |
+3.67% |
| 2005-12-31 | Skr16.68 Million ≈ $1.79 Million |
-- |
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using N… Read more